publication date: Mar. 30, 2018

Clinical Roundup Sorafenib improves PFS in rare sarcomas, NIH-funded study shows

Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released.

The trial was sponsored by the NCI, designed and conducted by the Alliance for Clinical Trials in Oncology, and supported by Bayer HealthCare AG, which provided the study drug.

Sorafenib is approved by FDA for the treatment of some patients with advanced kidney, liver, and thyroid cancer. The drug was chosen for this trial because in earlier retrospective studies of patients treated with sorafenib, desmoid tumors shrank, and patients had a reduction in pain and other symptoms.

The phase III double-blind clinical trial, designated as A091105, enrolled 87 patients with DT/DF between March 2014 and December 2016. To be eligible, patients had to have disease that could not be removed surgically, that had grown, or that was causing symptoms and met specific criteria.

Patients were randomly assigned to one of two treatment arms: one group received sorafenib (400 mg/day), and the other received a matched placebo. Patients in both groups continued treatment until … Continue reading Sorafenib improves PFS in rare sarcomas, NIH-funded study shows

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.